Pharmaceutical

UK MHRA approves AbbVie’s migraine prevention drug Aquipta

The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant) for the prophylaxis of migraine in adults.

Sep 5, 2023 - 20:00
UK MHRA approves AbbVie’s migraine prevention drug Aquipta
The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant) for the prophylaxis of migraine in adults.
Read the original article

Tags:

Previous Article

Cipla to bolster OTC portfolio with acquisition of Actor Pharma

Next Article

Chinese NMPA approves AstraZeneca’s Calquence for leukaemia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GLP-1 drugs not linked to suicidal thoughts in FDA’s early review

GLP-1 drugs not linked to suicidal thoughts in FDA’s ea...

Jan 12, 2024

Clinigen clears out cancer therapies in line with latest growth strategy

Clinigen clears out cancer therapies in line with lates...

Aug 12, 2023

FDA grants approval for first time to a home test for chlamydia and gonorrhea

FDA grants approval for first time to a home test for c...

Nov 15, 2023